Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 11, 2025, Janux Therapeutics, Inc. (the "Company") held the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2025, the record date for the Annual Meeting, 59,168,490 shares of common stock were outstanding and entitled to vote at the Annual Meeting, of which 56,239,312 shares of common stock were present virtually or represented by proxy at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

Proposal 1: Election of Directors

The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

Proposal 3: Advisory Vote on Executive Compensation

The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement. The final voting results are as follows:

Proposal 4: Advisory Vote on the Frequency of Future Advisory Stockholder Votes on Executive Compensation

The Company's stockholders approved, on an advisory (non-binding) basis, the frequency of future advisory stockholder votes on executive compensationas disclosed in the Proxy Statement. The final voting results are as follows: